International Journal of Legal Medicine

, Volume 130, Issue 1, pp 127–138 | Cite as

The pharmacology and toxicology of kratom: from traditional herb to drug of abuse

  • Marcus L. Warner
  • Nellie C. Kaufman
  • Oliver Grundmann
Review
First Online:
Received:
Accepted:

Abstract

Mitragyna speciosa (Rubiaceae), commonly known as kratom, is a tropical tree with a long history of traditional use in parts of Africa and Southeast Asia. In recent years, kratom has gained popularity for use as a recreational drug across the globe. Relatively new to the illicit market and used in a manner different from its traditional applications, preparations of kratom are touted by many as a safe and legal psychoactive product that improves mood, relieves pain, and may provide benefits in opiate addiction. Available literature was reviewed for M. speciosa via PubMed, Google Scholar, CINAHL, and EBSCO to summarize its traditional uses, phytochemical composition, pharmacology and toxicology of proposed active constituents, and potential for misuse and abuse. Research has demonstrated that both stimulant and sedative dose-dependent effects do exist, but a growing concern for the drug’s effects and safety of use has resulted in national and international attention primarily due to an increase in hospital visits and deaths in several countries that are said to have been caused by extracts of the plant. The main active alkaloid substances in kratom, mitragynine and 7-hydroxymitragynine, present with a range of CNS stimulant and depressant effects mediated primarily through monoaminergic and opioid receptors. Recently, Palm Beach County, located in the southeastern corridor of Florida, has considered regulating kratom due to public safety concerns following the death of a young adult. At the local, state, and even federal levels, governments are now being confronted with the task of determining the safety and the possible regulation of kratom extracts. There are currently no standard analytical screening techniques for mitragynine and its metabolites following ingestion limiting its detection to more sophisticated techniques like liquid chromatography-mass spectrometry to determine kratom use. The growing concern of the abuse potential of kratom requires careful evaluation of its benefits and potential toxicities.

Keywords

Kratom Stimulant Mitragyna speciosa Psychoactive Drug abuse 
This is a preview of subscription content, log in to check access

References

  1. 1.
    Richardson WH 3rd, Slone CM, Michels JE (2007) Herbal drugs of abuse: an emerging problem. Emerg Med Clin North Am 25(2):435–457PubMedCrossRefGoogle Scholar
  2. 2.
    Jerry J, Collins G, Streem D (2012) Synthetic legal intoxicating drugs: the emerging ‘incense’ and ‘bath salt’ phenomenon. Cleve Clin J Med 79:258–264PubMedCrossRefGoogle Scholar
  3. 3.
    Rosenbaum CD, Carreiro SP, Babu KM (2012) Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 8:15–32PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Tanguay P (2011) Kratom in Thailand: decriminalisation and community control? Series on Legislative Reform of Drug Policies No. 13, Transnational Institute. https://www.tni.org/files/download/kratom-briefing-dlr13.pdf. Accessed 26 Aug 2015
  5. 5.
    Shellard EJ (1989) Ethnopharmacology of kratom and the Mitragyna alkaloids. J Ethnopharmacol 25:123–124PubMedCrossRefGoogle Scholar
  6. 6.
    Kratom (Mitragyna speciosa Korth) Drug Enforcement Administration, Office of Diversion Control, Drug & Chemical Evaluation Section, Springfield, VA: US Government Printing Office (2013). http://www.deadiversion.usdoj.gov/drug_chem_info/kratom.pdf. Accessed 26 Aug 2015
  7. 7.
    Hassan Z, Muzaimi M, Navaratnam V et al (2013) From kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev 37:138–151PubMedCrossRefGoogle Scholar
  8. 8.
    Kratom (Mitragyna speciosa) drug profile. European Monitoring Centre for Drugs and Drug Addiction, January, 2015. http://www.emcdda.europa.eu/publications/drug-profiles/kratom. Accessed 26 Aug 2015
  9. 9.
    Beckett AH, Shellard EJ, Phillipson JD et al (1965) Alkaloids from Mitragyna speciosa (Korth.). J Pharm Pharmacol 17:753–755PubMedCrossRefGoogle Scholar
  10. 10.
    Assanangkornchai S, Pattanasattayawong U, Samangsri N et al (2007) Substance use among high-school students in Southern Thailand: trends over 3 years (2002–2004). Drug Alcohol Depend 86:167–174PubMedCrossRefGoogle Scholar
  11. 11.
    Boyer EW, Babu KM, Adkins JE et al (2008) Self-treatment of opioid withdrawal using kratom (Mitragyna speciosa Korth). Addiction 103:1048–1050PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Jansen KL, Prast CJ (1988) Ethnopharmacology of kratom and the Mitragyna alkaloids. J Ethnopharmacol 23:115–119PubMedCrossRefGoogle Scholar
  13. 13.
    Parthasarathy S, Bin Azizi J, Ramanathan S et al (2009) Evaluation of antioxidant and antibacterial activities of aqueous, methanolic and alkaloid extracts from Mitragyna speciosa (Rubiaceae family) leaves. Molecules 14:3964–3974PubMedCrossRefGoogle Scholar
  14. 14.
    Chan KB, Pakiam C, Rahim RA (2005) Psychoactive plant abuse: the identification of mitragynine in ketum and in ketum preparations. Bull Narc 57:249–256PubMedGoogle Scholar
  15. 15.
    Forrester MB (2013) Kratom exposures reported to Texas poison centers. J Addict Dis 32:396–400PubMedCrossRefGoogle Scholar
  16. 16.
    Mowry JB, Spyker DA, Cantilena LR Jr et al (2014) 2013 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 31st annual report. Clin Toxicol (Phila) 52:1032–1283CrossRefGoogle Scholar
  17. 17.
    Ingsathit A, Woratanarat P, Anukarahanonta T et al (2009) Prevalence of psychoactive drug use among drivers in Thailand: a roadside survey. Accid Anal Prev 41:474–478PubMedCrossRefGoogle Scholar
  18. 18.
    Suttajit S, Kittirattanapaiboon P, Junsirimongkol B et al (2012) Risks of major depressive disorder and anxiety disorders among Thais with alcohol use disorders and illicit drug use: findings from the 2008 Thai National Mental Health survey. Addict Behav 37:1395–1399PubMedCrossRefGoogle Scholar
  19. 19.
    Vimont C (2011) Addictive substance called kratom becoming popular in South Florida. http://www.drugfree.org/join-together/addictive-substance-called-kratom-becoming-popular-in-south-florida/. Accessed 26 Aug 2015
  20. 20.
    Babu KM, McCurdy CR, Boyer EW (2008) Opioid receptors and legal highs: Salvia divinorum and kratom. Clin Toxicol (Phila) 46:146–152CrossRefGoogle Scholar
  21. 21.
    Prozialeck WC, Jivan JK, Andurkar SV (2012) Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc 112:792–799PubMedGoogle Scholar
  22. 22.
    Philipp AA, Wissenbach DK, Weber AA et al (2010) Phase I and II metabolites of speciogynine, a diastereomer of the main kratom alkaloid mitragynine, identified in rat and human urine by liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry. J Mass Spectrom 45:1344–1357PubMedCrossRefGoogle Scholar
  23. 23.
    Kapp FG, Maurer HH, Auwarter V et al (2011) Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). J Med Toxicol 7:227–231PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Takayama H (2004) Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull (Tokyo) 52:916–928CrossRefGoogle Scholar
  25. 25.
    Kong WM, Chik Z, Ramachandra M et al (2011) Evaluation of the effects of Mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay. Molecules 16:7344–7356PubMedCrossRefGoogle Scholar
  26. 26.
    Huus K (2012) Asian leaf “kratom” making presence felt in US emergency rooms. NBC News, March 19. http://usnews.nbcnews.com/_news/2012/03/19/10760892-asian-leaf-kratom-making-presence-felt-in-us-emergency-rooms. Accessed 26 Aug 2015
  27. 27.
    Neerman MF, Frost RE, Deking J (2013) A drug fatality involving kratom. J Forensic Sci 58(Suppl 1):S278–S279PubMedCrossRefGoogle Scholar
  28. 28.
    Trakulsrichai S, Sathirakul K, Auparakkitanon S et al (2015) Pharmacokinetics of mitragynine in man. Drug Des Devel Ther 9:2421–2429PubMedPubMedCentralGoogle Scholar
  29. 29.
    Scott TM, Yeakel JK, Logan BK (2014) Identification of mitragynine and O-desmethyltramadol in kratom and legal high products sold online. Drug Test Anal 6:959–963PubMedCrossRefGoogle Scholar
  30. 30.
    Maruyama T, Kawamura M, Kikura-Hanajiri R et al (2009) The botanical origin of kratom (Mitragyna speciosa; Rubiaceae) available as abused drugs in the Japanese markets. J Nat Med 63:340–344PubMedCrossRefGoogle Scholar
  31. 31.
    Janchawee B, Keawpradub N, Chittrakarn S et al (2007) A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats. Biomed Chromatogr 21:176–183PubMedCrossRefGoogle Scholar
  32. 32.
    National Forensic Laboratory Information System: year 2013 annual report. Springfield, VA: U.S. Drug Enforcement Administration, Office of Diversion Control (2014). http://www.deadiversion.usdoj.gov/nflis/NFLIS2013AR.pdf. Accessed 26 Aug 2015
  33. 33.
    Harizal SN, Mansor SM, Hasnan J et al (2010) Acute toxicity study of the standardized methanolic extract of Mitragyna speciosa Korth in rodent. J Ethnopharmacol 131:404–409PubMedCrossRefGoogle Scholar
  34. 34.
    Chittrakarn S, Sawangjaroen K, Prasettho S et al (2008) Inhibitory effects of kratom leaf extract (Mitragyna speciosa Korth.) on the rat gastrointestinal tract. J Ethnopharmacol 116:173–178PubMedCrossRefGoogle Scholar
  35. 35.
    Kronstrand R, Roman M, Thelander G et al (2011) Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol 35:242–247PubMedCrossRefGoogle Scholar
  36. 36.
    McWhirter L, Morris S (2010) A case report of inpatient detoxification after kratom (Mitragyna speciosa) dependence. Eur Addict Res 16:229–231PubMedCrossRefGoogle Scholar
  37. 37.
    Limsuwanchote S, Wungsintaweekul J, Keawpradub N et al (2014) Development of indirect competitive ELISA for quantification of mitragynine in kratom (Mitragyna speciosa (Roxb.) Korth.). Forensic Sci Int 244:70–77PubMedCrossRefGoogle Scholar
  38. 38.
    Wang M, Carrell EJ, Ali Z et al (2014) Comparison of three chromatographic techniques for the detection of mitragynine and other indole and oxindole alkaloids in Mitragyna speciosa (kratom) plants. J Sep Sci 37:1411–1418PubMedCrossRefGoogle Scholar
  39. 39.
    Philipp AA, Meyer MR, Wissenbach DK et al (2011) Monitoring of kratom or Krypton intake in urine using GC-MS in clinical and forensic toxicology. Anal Bioanal Chem 400:127–135PubMedCrossRefGoogle Scholar
  40. 40.
    Lesiak AD, Cody RB, Dane AJ et al (2014) Rapid detection by direct analysis in real time-mass spectrometry (DART-MS) of psychoactive plant drugs of abuse: the case of Mitragyna speciosa aka “kratom”. Forensic Sci Int 242:210–218PubMedCrossRefGoogle Scholar
  41. 41.
    Designer drugs. The trends report 2014. NMS Laboratories. http://www.nmslabs.com/uploads/PDF/Designer_Drug_Trends_February_2014.pdf. Accessed 26 Aug 2015
  42. 42.
    Kiley B (2012) The rush to prohibit kratom. The Stranger, Seattle. http://www.thestranger.com/seattle/the-rush-to-prohibit-kratom/Content?oid=13321119. Accessed 26 Aug 2015
  43. 43.
    Holler JM, Vorce SP, McDonough-Bender PC et al (2011) A drug toxicity death involving propylhexedrine and mitragynine. J Anal Toxicol 35:54–59PubMedCrossRefGoogle Scholar
  44. 44.
    McIntyre IM, Trochta A, Stolberg S et al (2015) Mitragynine ‘kratom’ related fatality: a case report with postmortem concentrations. J Anal Toxicol 39:152–155PubMedCrossRefGoogle Scholar
  45. 45.
    Drugs of abuse: a DEA resource guide (2015) Drug Enforcement Administration, National Drug Threat Assessment, US Government Printing Office. http://www.dea.gov/resource-center/dir-ndta-unclass.pdf. Accessed 26 Aug 2015
  46. 46.
    Detention without physical examination of dietary supplements and bulk dietary ingredients that are or contain Mitragyna speciosa or kratom. U.S. Food and Drug Administration, Silver Spring, MD (2014). http://www.accessdata.fda.gov/cms_ia/importalert_1137.html. Accessed 26 Aug 2015
  47. 47.
    Ciupagea A (2015) The challenge of new psychoactive substances—global SMART Programme. United Nations Office on Drugs and Crime. https://www.unodc.org/documents/scientific/NPS_2013_SMART.pdf. Accessed 26 Aug 2015
  48. 48.
    Online sales of new psychoactive substances / ‘legal highs’: summary of results from the 2011 multilingual snapshots. European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 2011. http://www.emcdda.europa.eu/publications/scientific-studies/2011/snapshot. Accessed 26 Aug 2015
  49. 49.
    Henman A, Metaal P (2014) Time for a wake-up call: an historical and ethnographic approach to the regulation of plant-based stimulants. Series on Legislative Reform on Drug Policies No. 27, Transnational Institute. https://www.tni.org/en/briefing/time-wake-call-historical-and-ethnographic-approach-regulation-plant-based-stimulants. Accessed 26 Aug 2015
  50. 50.
    Raffa RB (2014) Kratom and other mitragynines: the chemistry and pharmacology of opioids from a non-opium source. CRC, Boca RatonCrossRefGoogle Scholar
  51. 51.
    Long J (2014) FDA, States mount war on kratom. Natural Products Insider. http://www.naturalproductsinsider.com/news/2014/03/fda-states-mount-war-on-kratom.aspx. Accessed 26 Aug 2015
  52. 52.
    Hong A (2014) Drug agency monitors kratom use in Oklahoma. Fox23. http://www.fox23.com/news/news/local/drug-agency-monitors-kratom-use-oklahoma/ngftf/. Accessed 26 Aug 2015
  53. 53.
    Designer Drugs Ordinance, Ordinance No. 2014-013, Sarasota County Government (2014). https://www.scgov.net/HumanServices/Documents/Designer%20Drugs%20Ordinance.pdf. Accessed 26 Aug 2015
  54. 54.
    Gertrude J (2014) Toxicology report, VX48762. Melbourne, FL. http://speciosa.org/wp-content/uploads/2014/10/IAN-MAUTNER-14-0759-3.pdf. Accessed 26 Aug 2015
  55. 55.
    Wingham II J (2014) Boynton Beach I-95 suicide victim had kratom in his system, tests confirm. Palm Beach Post. http://www.palmbeachpost.com/news/news/local/i-95-suicide-victim-had-kratom-in-his-system/nhZX9/. Accessed 26 Aug 2015
  56. 56.
    Wallman B (2014) Broward opts not to ban kratom for now. Sun Sentinel. http://www.sun-sentinel.com/local/broward/fl-kratom-ban-broward-20141028-story.html. Accessed 26 Aug 2015
  57. 57.
    Bennett G (2014) Anti-drug crusading AG meets woman who blames son’s death on kratom. Palm Beach Post. http://www.mypalmbeachpost.com/news/news/local/anti-drug-crusading-ag-meets-woman-who-blames-sons/ng627/. Accessed 26 Aug 2015
  58. 58.
    LaGrone K (2014) Kratom ban? Palm Beach County commissioners could order warning labels, age limits or issue a ban. WPTV. http://www.wptv.com/news/local-news/investigations/kratom-ban-palm-beach-county-commissioners-could-order-warning-labels-age-limits-or-issue-a-ban. Accessed 26 Aug 2015
  59. 59.
    Greenemeier L (2013) Should kratom use be legal? Scientific American. http://www.scientificamerican.com/article/should-kratom-be-legal/. Accessed 26 Aug 2015
  60. 60.
    Kratom, H.B. 5526, Illinois General Assembly (2014). http://www.ilga.gov/legislation/BillStatus.asp?DocNum=5526&GAID=12&DocTypeID=HB&SessionID=85&GA=98. Accessed 26 Aug 2015
  61. 61.
    Criminal Code, H.B. 2453, Arizona House of Representatives (2014). http://www.azleg.gov/legtext/51leg/2r/laws/0036.pdf. Accessed 26 Aug 2015

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Marcus L. Warner
    • 1
  • Nellie C. Kaufman
    • 1
  • Oliver Grundmann
    • 1
  1. 1.Department of Medicinal Chemistry, College of PharmacyUniversity of FloridaGainesvilleUSA

Personalised recommendations